STTK — Shattuck Labs Share Price
0.000.00%
Last trade - 00:00- $47.69m
- -$25.29m
- $5.72m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.6 | ||
| Price to Tang. Book | 0.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -98.09% | ||
| Return on Equity | -67.23% | ||
| Operating Margin | -1408.27% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.93 | 30.02 | 0.65 | 1.66 | 5.72 | n/a | n/a | -10.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Directors
- George Golumbeski CHM (63)
- Taylor Schreiber CEO (41)
- Andrew Neill CFO (35)
- Erin Thomson GCN (41)
- Casi Deyoung OTH (50)
- Arundathy Pandite OTH (62)
- Carrie Brownstein DRC (51)
- Helen Boudreau IND (55)
- Tyler Brous IND (38)
- Neil Gibson IND (65)
- Michael Lee IND (42)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 2016
- Public Since
- October 9th, 2020
- No. of Shareholders
- 23
- No. of Employees
- 44
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 47,899,240
- Address
- 500 W. 5Th Street, Suite 100, AUSTIN, 78701
- Web
- https://www.shattucklabs.com/
- Phone
- +1 5129004690
- Contact
- Conor Richardson
- Auditors
- KPMG LLP
Upcoming Events for STTK
Q2 2025 Shattuck Labs Inc Earnings Release
Similar to STTK
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Shattuck Labs share price?
As of Today at 23:12 UTC, shares in Shattuck Labs are trading at $1.00. This share price information is delayed by 15 minutes.
How has the Shattuck Labs share price performed this year?
Shares in Shattuck Labs last closed at $1.00 and the price had moved by -91.03% over the past 365 days. In terms of relative price strength the Shattuck Labs share price has underperformed the S&P500 Index by -91.91% over the past year.
What are the analyst and broker recommendations for Shattuck Labs?
The overall consensus recommendation for Shattuck Labs is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Shattuck Labs dividend yield?
Shattuck Labs does not currently pay a dividend.
Does Shattuck Labs pay a dividend?
Shattuck Labs does not currently pay a dividend.
When does Shattuck Labs next pay dividends?
Shattuck Labs does not currently pay a dividend.
How do I buy Shattuck Labs shares?
To buy shares in Shattuck Labs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Shattuck Labs?
As of the previous close price of $1.00, shares in Shattuck Labs had a market capitalisation of $47.69m.
Where are Shattuck Labs shares listed?
Here are the trading details for Shattuck Labs:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: STTK
What kind of share is Shattuck Labs?
Based on an overall assessment of its quality, value and momentum Shattuck Labs is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Shattuck Labs share price forecast for 2025?
The analyst consensus target price for shares in Shattuck Labs is $2.46. That is 147.06% above the last closing price of $1.00.
Analysts covering Shattuck Labs currently have a consensus Earnings Per Share (EPS) forecast of -$1.12 for the next financial year.
Find out moreWhat is the trend in the Shattuck Labs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shattuck Labs. Over the past six months, its share price has underperformed the S&P500 Index by -19.98%.
As of the last closing price of $1.00, shares in Shattuck Labs were trading -45.97% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Shattuck Labs PE Ratio?
The Shattuck Labs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Shattuck Labs?
Shattuck Labs' management team is headed by:
- George Golumbeski - CHM
- Taylor Schreiber - CEO
- Andrew Neill - CFO
- Erin Thomson - GCN
- Casi Deyoung - OTH
- Arundathy Pandite - OTH
- Carrie Brownstein - DRC
- Helen Boudreau - IND
- Tyler Brous - IND
- Neil Gibson - IND
- Michael Lee - IND